← All trials
NCT07012109
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2025
- Primary completion
- Jan 31, 2028
- Completion date
- Jul 31, 2028
- First posted
- Jun 10, 2025
- Last posted
- Jun 10, 2025
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou BeBetter Medicine Technology Co, LTDLead sponsor
- Zhejiang UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.